Although AOM liraglutide (Saxenda) has been approved for treatment of obesity in adolescents since late 2020 ( 5 ), the approval of AOM semaglutide (Wegovy) in December 2022 for treatment of obesity for adolescents prompted new excitement ( 6 )
Its necessary to consult a healthcare provider to ensure the treatment suits the patients needs and concerns
This weight loss is typically gradual, occurring over several months, and can vary from person to person
Some people who use B12 Nasal Spray get headaches, feel sick, have a runny nose or get infections
It is generally prescribed for individuals classified as obese with a BMI of 30 or higher, or for those overweight with a BMI of 27 or higher and with a weight-related health condition
Control targets Achieving good glycemic control may avoid or delay the appearance of micro- and macrovascular complications, as has been shown by different studies involving long periods of follow-up.11 It is therefore recommended that very strict control should be achieved in the early stages of diabetes management (glycosylated hemoglobin [HbA1c] 8.5% in symptomatic patients
